Status:
COMPLETED
Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia
Lead Sponsor:
Response Pharmaceuticals
Conditions:
Hyperlipidemia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether SLx-4090 in combination with statin therapy will reduce LDL-C in patients with hyperlipidemia more effectively than statin therapy alone.
Detailed Description
1. LDL-C after 12 weeks of treatment 2. Safety and tolerability 3. Plasma levels of SLx-4090
Eligibility Criteria
Inclusion
- LDL-C \> or = 100 mg/dL
- On stable statin therapy for at least 6 weeks
Exclusion
- Coronary heart disease or risk factors for CHD
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
133 Patients enrolled
Trial Details
Trial ID
NCT00810979
Start Date
January 1 2009
End Date
September 1 2009
Last Update
November 18 2023
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35209
2
Tempe, Arizona, United States, 85282
3
Tucson, Arizona, United States, 85710
4
Jacksonville, Florida, United States, 32205